Lakefront Biotherapeutics NV annual report, Q4 FY2018

Business context and reporting period

The supplied filing is a Form 20-F for Galapagos NV, not Lakefront Biotherapeutics NV. It reports the fiscal year ended December 31, 2018; the source does not provide a separate fourth-quarter report. Galapagos is a Belgium-based clinical-stage biopharmaceutical company using a proprietary target-discovery platform to develop medicines for inflammation, fibrosis, osteoarthritis and other diseases. The company had no approved products or historical product sales.

The audited consolidated financial statements are presented in euros under IFRS as issued by the IASB. The company reported 54,465,421 ordinary shares outstanding at December 31, 2018 and had 725 employees.

Financial performance and liquidity

Metric20182017Change
Revenue€288.8 million€127.1 millionUp 127%
Other income€29.0 million€28.8 millionUp 1%
Total revenue and other income€317.8 million€155.9 millionUp 104%
Research and development expense€322.9 million€218.5 millionUp 48%
Total operating expenses€362.7 million€245.7 millionUp 48%
Operating loss€44.8 million€89.8 millionLoss reduced 50%
Net loss€29.3 million€115.7 millionLoss reduced 75%
Basic and diluted loss per share€0.56 loss€2.34 lossImproved
Operating cash flow€142.5 million outflow€147.0 million outflowOutflow reduced €4.6 million
Cash flow from financing€287.9 million inflow€353.4 million inflowDown €65.5 million
Cash and cash equivalents€1.291 billion€1.151 billionUp €139.6 million

Revenue was primarily collaboration-related rather than product revenue: €196.5 million from upfront payments and license fees, €73.4 million from milestones, €8.7 million from reimbursement income and €10.2 million from other revenue, including fee-for-service activities. Major 2018 items included recognition of a €47.5 million Novartis upfront payment for MOR106, €38.0 million of the restructured AbbVie upfront payment, Gilead-related revenue and a €9.0 million Servier milestone.

R&D spending was concentrated on the filgotinib program (€66.1 million), proprietary GLPG1690 IPF development (€72.7 million), the CF program (€30.1 million), GLPG1972 (€15.8 million), MOR106 (€15.0 million) and other programs (€123.1 million). Capital expenditures were €13.7 million, compared with €7.4 million in 2017.

At year-end, total assets were €1.439 billion, total equity was €1.214 billion and total liabilities were €225.2 million. The company reported no long-term debt and stated that it had no credit lines. Cash included $320.5 million held in U.S. dollars, creating foreign-exchange exposure.

Material changes versus the prior comparable period

  • Revenue increased sharply because of collaboration and license-related recognition, including the Novartis MOR106 transaction and additional AbbVie consideration.
  • IFRS 15 was adopted on January 1, 2018 using the modified retrospective method. Opening accumulated losses and deferred income each increased by €83.2 million. Reported 2018 revenue was €288.8 million versus €232.8 million under the former IAS 18 approach, a €56.0 million accounting difference.
  • R&D investment increased 48%, driven particularly by the proprietary GLPG1690 IPF program and growing clinical-stage activity.
  • Financing inflows included €280.2 million of net proceeds from a September 2018 U.S. follow-on offering and €7.7 million from warrant exercises. The prior year included €348.1 million from a U.S. offering.
  • Cash increased despite operating cash burn because equity financing and collaboration receipts exceeded operating and investing outflows.
  • Deferred income declined to €149.8 million from €219.9 million, principally because collaboration consideration was recognized as performance obligations were satisfied.
  • Net financial income was €15.6 million in 2018, compared with net financial expense of €25.7 million in 2017. The change was primarily due to foreign-exchange effects: a €9.9 million net foreign-exchange gain in 2018 versus a €27.4 million net loss in 2017.

Guidance, outlook, commentary and risks

Management stated that existing cash and cash equivalents were expected to fund operating expenses and capital expenditures for at least the next two to three years, or at least through the next three years in another disclosure. This estimate depends on development spending, clinical progress, collaboration payments and other assumptions and could be shortened by higher or faster spending. The company expected continued losses and no product-sales revenue for the foreseeable future.

Key development priorities included Phase 3 filgotinib programs in rheumatoid arthritis, Crohn’s disease and ulcerative colitis; Phase 3 ISABELA trials for GLPG1690 in idiopathic pulmonary fibrosis; Phase 2 programs for GLPG1205, GLPG1972 and MOR106; and early development of GLPG3312 and other pipeline candidates. Filgotinib was being developed primarily with Gilead, MOR106 with Novartis and MorphoSys, GLPG1972 with Servier, and cystic-fibrosis programs with AbbVie.

Principal risks include clinical-trial failure or delay, regulatory rejection, safety findings involving filgotinib or other candidates, reliance on Gilead and other collaboration partners, dependence on contract research organizations and third-party manufacturers, intellectual-property challenges, competition, reimbursement and pricing uncertainty, foreign-exchange volatility, cybersecurity and data-protection compliance, and the need for substantial future capital. Filgotinib faced particular safety and regulatory uncertainty relating to potential male reproductive effects and possible dose or labeling restrictions.

The company had €227.2 million of contractual obligations and commitments at December 31, 2018, including €27.7 million of operating lease obligations and €199.5 million of purchase commitments. A separate Gilead cost-sharing commitment amounted to €74.0 million. A former subsidiary director’s €1.5 million wrongful-termination claim remained on appeal; management assessed the risk as possible but not probable and recorded no provision.

The company adopted IFRS 16 on January 1, 2019 and estimated recognition of approximately €26.3 million of right-of-use assets and lease liabilities. It expected an immaterial effect on net income, with approximately €4.9 million of cash-flow presentation shifting from operating to financing activities.

Most important facts an investor should verify

  • Confirm the issuer identity: the supplied filing is for Galapagos NV, while the request metadata names Lakefront Biotherapeutics NV.
  • Use annual fiscal-year figures rather than Q4 figures; the filing covers the year ended December 31, 2018 and does not present a standalone fourth quarter.
  • Separate recurring operating performance from collaboration-driven revenue and accounting effects under IFRS 15.
  • Review the sustainability and timing of the €1.291 billion cash balance against expected clinical spending, the €74.0 million Gilead cost-sharing commitment and €227.2 million of other contractual obligations.
  • Assess clinical, regulatory and safety outcomes for filgotinib, GLPG1690 and other lead candidates before assigning value to potential milestones, royalties or future product revenue.
  • Verify the status of the former director’s appeal and any potential exposure under collaboration, tax-credit, grant, intellectual-property or product-liability arrangements.
  • Monitor dilution from the 4.63 million outstanding warrants, the 2018 equity offering and any additional financing that may be required.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.